Skip to main content
. 2023 Nov 20;11(11):e007736. doi: 10.1136/jitc-2023-007736

Figure 6.

Figure 6

Anti-PD-1-responsive human metastatic melanoma tumors express lower levels of JARID2 mRNA compared with non-responders. (A) Heatmap representing human melanoma RNA sequencing z-scores of genes relevant to PRC2, T cells, and antigen presentation by MHC-I and MHC-II. Samples were ordered by increasing JARID2 mRNA expression. (B) Summation scores of Z-standardized T-cell signature genes stratified by median JARID2 mRNA. (C) Summation scores of Z-standardized MHC-II signature genes stratified by median JARID2 mRNA. (D) Z-standardized JARID2 mRNA stratified by tumor-specific (IHC) HLA-DR status using a defined 5% cut-off. (E–G) JARID2 mRNA expression z-scores in responders (complete response/partial response) compared with non-responders (progressive disease/stable disease) in patients given anti-PD-1. Mann-Whitney tests, *p<0.05. CIITA, class II major histocompatibility complex transactivator II; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; EZH2, enhancer of zeste 2 polycomb repressive complex 2 subunit; HLA-DR, human leukocyte antigen-DR; IHC, immunohistochemistry; JARID2, Jumoni and AT-rich interaction domain-containing protein; MHC, major histocompatibility complexes; mRNA, messenger RNA; PD-1, programmed death-1; PRC2, polycomb repressive complex 2.